Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-12-25

Clinical Trial Update: BAY38-9456, 5/10/20mg, vs.Placebo in Erectile Dysfunction [Phase 4]

View source ↗

Summary

A Phase 4 randomized trial comparing BAY38-9456 at 5 mg and 10 mg to placebo for erectile dysfunction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BAY38-9456

Snippet

Sponsor: Bayer | Conditions: Erectile Dysfunction | Phase 4 | Status: COMPLETED